SC
RARE icon

SummitTX Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

SummitTX Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.29M Buy
+347,760
New +$7.83M 0.23% 106
2025
Q2 		– Sell
-20,085
Closed -$727K – 972
2025
Q1 		$727K Buy
+20,085
New +$836K 0.03% 457

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

SummitTX Capital's RARE Position: Q1 2026 in Review

SummitTX Capital opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 347,760 shares worth $7.29M. The stake represents 0.23% of the portfolio and ranks #106 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in RARE as recently as Q1 2025.

SummitTX Capital first reported a position in RARE in Q1 2025 and has held it in 2 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • SummitTX Capital held 347,760 shares of Ultragenyx Pharmaceutical worth $7.29M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new SummitTX Capital position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.23% of SummitTX Capital's portfolio in Q1 2026, its #106 holding.
  • SummitTX Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 2 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.